Neurocrine Biosciences (NBIX) Competitors $119.57 +0.45 (+0.38%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, UTHR, INCY, EXEL, BMRN, EXAS, RGEN, HALO, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment. Is NBIX or ALNY more profitable? Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences14.49% 13.38% 9.73% Alnylam Pharmaceuticals -12.37%N/A -6.83% Do analysts rate NBIX or ALNY? Neurocrine Biosciences currently has a consensus price target of $162.00, suggesting a potential upside of 36.00%. Alnylam Pharmaceuticals has a consensus price target of $319.17, suggesting a potential upside of 10.44%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Which has higher valuation and earnings, NBIX or ALNY? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.41B4.89$341.30M$2.9540.38Alnylam Pharmaceuticals$2.35B16.05-$278.16M-$2.09-138.28 Does the MarketBeat Community prefer NBIX or ALNY? Alnylam Pharmaceuticals received 123 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.68% of users gave Neurocrine Biosciences an outperform vote while only 76.32% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeurocrine BiosciencesOutperform Votes104477.68% Underperform Votes30022.32% Alnylam PharmaceuticalsOutperform Votes116776.32% Underperform Votes36223.68% Does the media favor NBIX or ALNY? In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 20 mentions for Alnylam Pharmaceuticals and 19 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.40 beat Alnylam Pharmaceuticals' score of 1.27 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 17 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 14 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in NBIX or ALNY? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, NBIX or ALNY? Neurocrine Biosciences has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.79B$2.93B$5.33B$8.39BDividend YieldN/A1.64%5.21%4.11%P/E Ratio36.2131.1826.7119.71Price / Sales4.89398.78386.46120.65Price / Cash34.35168.6838.2534.62Price / Book4.593.236.774.50Net Income$341.30M-$72.35M$3.23B$248.22M7 Day Performance-1.57%2.49%0.48%-0.78%1 Month Performance15.34%2.45%9.10%11.53%1 Year Performance-15.22%-24.98%18.56%8.99% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8714 of 5 stars$119.57+0.4%$162.00+35.5%-14.6%$11.83B$2.41B36.321,200Positive NewsALNYAlnylam Pharmaceuticals4.1797 of 5 stars$291.86+2.3%$319.17+9.4%+91.5%$38.06B$2.35B-134.502,000Positive NewsBIIBBiogen4.8942 of 5 stars$129.44+3.1%$191.30+47.8%-43.9%$18.97B$9.82B11.578,720Positive NewsUTHRUnited Therapeutics4.9772 of 5 stars$305.310.0%$392.00+28.4%+11.7%$13.77B$2.99B13.41980Positive NewsAnalyst RevisionINCYIncyte4.8728 of 5 stars$63.81+0.8%$73.53+15.2%+10.8%$12.35B$4.41B236.342,320Positive NewsEXELExelixis4.094 of 5 stars$44.69-1.6%$38.94-12.9%+104.1%$12.19B$2.30B25.251,220Positive NewsInsider TradeBMRNBioMarin Pharmaceutical4.9421 of 5 stars$59.41+0.2%$93.45+57.3%-24.1%$11.39B$2.95B27.003,080Positive NewsInsider TradeEXASExact Sciences4.6351 of 5 stars$56.94+0.9%$70.90+24.5%+5.6%$10.74B$2.83B-10.226,400Positive NewsRGENRepligen4.821 of 5 stars$126.19-0.2%$173.25+37.3%-27.1%$7.09B$650.43M-247.432,020Positive NewsGap DownHALOHalozyme Therapeutics4.8553 of 5 stars$53.29+2.4%$61.90+16.2%+18.2%$6.57B$1.08B15.54390MDGLMadrigal Pharmaceuticals4.5252 of 5 stars$290.72-0.1%$416.33+43.2%+16.3%$6.45B$317.38M-11.5990Positive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts